Lumos Pharma Inc expected to post a loss of $1.01 a share - Earnings Preview

Lumos Pharma

11/11/2022 22:14

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a
rise
in quarterly revenue when it reports  results on November 10
(estimated). 
    * The Austin Texas-based  company is expected to report
revenue of
$57.14 thousand, according to the mean estimate from 7 analysts,
based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Lumos Pharma Inc is
for a
loss of $1.01 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lumos
Pharma Inc
is $22.5​, above​ its last closing price of $9.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.98       -0.99      -0.94     Beat    4.6
 Mar. 31 2022  -0.89       -0.89      -0.92     Missed  -3.1
 Dec. 31 2021              -0.92      -0.67     Beat    27​
 Sep. 30 2021  -1.07       -1.07      -0.90     Beat    16
 ​​Jun.        -1.05       -1.03      -1.04     Missed  -0.6
 30 2021                                                
 Mar. 31 2021  -0.88       -0.87      -1.04     Missed  -19​
 Dec. 31 2020  -0.86       -0.86      -0.31     Beat    64
 Sep. 30 2020  -0.66       -0.64      0.21      Beat    132.6
 This summary was machine generated November 11 at 22:14 GMT. 
All figures in US dollars  unless otherwise stated